The contraceptive vaginal ring (NuvaRing) and hemostasis: a comparative study
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsMagnusdottir, E M
Bjarnadottir, R I
Onundarson, P T
Gudmundsdottir, B R
Geirsson, R T
Magnusdottir, S D
Dieben, Th O M
MetadataShow full item record
CitationContraception 2004, 69(6):461-7
AbstractThis open-label, nonrandomized study compared changes in hemostatic variables during NuvaRing and oral levonorgestrel 150 microg/ethinylestradiol 30 microg (LNG/EE) use for six cycles. Eighty-seven women started the study, 44 with NuvaRing and 43 with the LNG/EE oral contraceptive. For most procoagulation variables, there was no difference between NuvaRing and oral LNG/EE; only Factor VII levels increased in the NuvaRing group and decreased in the LNG/EE group. The majority of assessed variables show that anticoagulation and fibrinolytic activity was comparable between the NuvaRing and oral LNG/EE groups. Antithrombin activity and protein C activity both tended to be higher with NuvaRing. Levels of tissue plasminogen activator decreased in both groups but the reduction was smaller with NuvaRing. There were no significant differences in fibrin turnover between the treatment groups. The data show that both NuvaRing and oral LNG/EE are associated with a minimal effect on hemostatic variables.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 microg of ethinylestradiol and 100 microg of levonorgestrel with 30 microg of ethinylestradiol and 100 microg of levonorgestrel.
- Authors: Jespersen J, Endrikat J, Düsterberg B, Schmidt W, Gerlinger C, Wessel J, Sidelmann JJ, Skouby SO
- Issue date: 2005 Aug
- A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.
- Authors: Skouby SO, Endrikat J, Düsterberg B, Schmidt W, Gerlinger C, Wessel J, Goldstein H, Jespersen J
- Issue date: 2005 Feb
- Effect of four oral contraceptives on hemostatic parameters.
- Authors: Wiegratz I, Lee JH, Kutschera E, Winkler UH, Kuhl H
- Issue date: 2004 Aug
- The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study.
- Authors: Tuppurainen M, Klimscheffskij R, Venhola M, Dieben TO
- Issue date: 2004 May
- Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
- Authors: Sitruk-Ware RL, Menard J, Rad M, Burggraaf J, de Kam ML, Tokay BA, Sivin I, Kluft C
- Issue date: 2007 Jun